Global Recombinant Human Growth Hormone Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Recombinant Human Growth Hormone Market Insights, Forecast to 2034
Recombinant human growth hormone is produced by gene recombinant Escherichia coli secretory expression technology, and it is completely consistent with human pituitary growth hormone in amino acid content, sequence and protein structure. In the field of pediatrics, replacement therapy with recombinant human growth hormone can significantly promote children's height growth and improve the growth and development of various organs and tissues throughout the body. At the same time, recombinant human growth hormone also plays an important role in the fields of reproduction, burns and anti-aging.
Global Recombinant Human Growth Hormone market is expected to reach to US$ 4617 million in 2024, with a positive growth of %, compared with US$ 4268 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Recombinant Human Growth Hormone industry is evaluated to reach US$ 7400.2 million in 2029. The CAGR will be 8.2% during 2024 to 2029.
Globally, Recombinant Human Growth Hormone key manufacturers include Novo Nordisk, LG Chem, Pfizer, Eli lilly, Merck Serono, F.Hoffmann-La Roche, Ispen, Sandoz International and Changchun High-Tech Industries, etc. Novo Nordisk, LG Chem, Pfizer are top 3 players and held % sales share in total in 2022.
When considering the consumption regions, % volume of Recombinant Human Growth Hormone were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the sales share will be % in 2029. Moreover, China, plays a key role in the whole Recombinant Human Growth Hormone market and estimated to attract more attentions from industry insiders and investors.
Recombinant Human Growth Hormone can be divided into Powder Injection and Water Injection, etc. Powder Injection is the mainstream product in the market, accounting for % sales share globally in 2022 and the proportion will be % in 2029.
Recombinant Human Growth Hormone is widely used in various fields, such as Childhood Growth Hormone Deficiency, Chronic Renal Insufficiency, HIV Infection-Associated Wasting Syndrome and Adult GHD Replacement Therapy, etc. Childhood Growth Hormone Deficiency provides greatest supports to the Recombinant Human Growth Hormone industry development. In 2022, global % sales of Recombinant Human Growth Hormone went into Childhood Growth Hormone Deficiency filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global Recombinant Human Growth Hormone market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Recombinant Human Growth Hormone market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
Novo Nordisk
LG Chem
Pfizer
Eli lilly
Merck Serono
F.Hoffmann-La Roche
Ispen
Sandoz International
Changchun High-Tech Industries
Shenzhen Kexing Pharmaceutical
Changchun GeneScience Pharmaceutical
Anhui Anke Biotechnology
Segment by Type
Powder Injection
Water Injection
Childhood Growth Hormone Deficiency
Chronic Renal Insufficiency
HIV Infection-Associated Wasting Syndrome
Adult GHD Replacement Therapy
Small For Gestational Age (SGA)
Others
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Recombinant Human Growth Hormone plant distribution, commercial date of Recombinant Human Growth Hormone, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Recombinant Human Growth Hormone introduction, etc. Recombinant Human Growth Hormone Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Recombinant Human Growth Hormone
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Global Recombinant Human Growth Hormone market is expected to reach to US$ 4617 million in 2024, with a positive growth of %, compared with US$ 4268 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Recombinant Human Growth Hormone industry is evaluated to reach US$ 7400.2 million in 2029. The CAGR will be 8.2% during 2024 to 2029.
Globally, Recombinant Human Growth Hormone key manufacturers include Novo Nordisk, LG Chem, Pfizer, Eli lilly, Merck Serono, F.Hoffmann-La Roche, Ispen, Sandoz International and Changchun High-Tech Industries, etc. Novo Nordisk, LG Chem, Pfizer are top 3 players and held % sales share in total in 2022.
When considering the consumption regions, % volume of Recombinant Human Growth Hormone were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the sales share will be % in 2029. Moreover, China, plays a key role in the whole Recombinant Human Growth Hormone market and estimated to attract more attentions from industry insiders and investors.
Recombinant Human Growth Hormone can be divided into Powder Injection and Water Injection, etc. Powder Injection is the mainstream product in the market, accounting for % sales share globally in 2022 and the proportion will be % in 2029.
Recombinant Human Growth Hormone is widely used in various fields, such as Childhood Growth Hormone Deficiency, Chronic Renal Insufficiency, HIV Infection-Associated Wasting Syndrome and Adult GHD Replacement Therapy, etc. Childhood Growth Hormone Deficiency provides greatest supports to the Recombinant Human Growth Hormone industry development. In 2022, global % sales of Recombinant Human Growth Hormone went into Childhood Growth Hormone Deficiency filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global Recombinant Human Growth Hormone market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Recombinant Human Growth Hormone market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Novo Nordisk
LG Chem
Pfizer
Eli lilly
Merck Serono
F.Hoffmann-La Roche
Ispen
Sandoz International
Changchun High-Tech Industries
Shenzhen Kexing Pharmaceutical
Changchun GeneScience Pharmaceutical
Anhui Anke Biotechnology
Segment by Type
Powder Injection
Water Injection
Segment by Application
Childhood Growth Hormone Deficiency
Chronic Renal Insufficiency
HIV Infection-Associated Wasting Syndrome
Adult GHD Replacement Therapy
Small For Gestational Age (SGA)
Others
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Recombinant Human Growth Hormone plant distribution, commercial date of Recombinant Human Growth Hormone, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Recombinant Human Growth Hormone introduction, etc. Recombinant Human Growth Hormone Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Recombinant Human Growth Hormone
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices